Researchers have developed a novel method to enhance the ability of mesenchymal stromal cells (MSCs) to generate cartilage ...

For decades, Alzheimer's research has focused on examining amyloid plaques in the brain and prescribing antibody therapeutics that remove the plaques to slow cognitive decline in patients.

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Persistent pain is common in rheumatoid arthritis. But patient-reported outcomes tools can help clinicians determine a care plan.

Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

Arthritis, often thought to be an ailment of the elderly, is an autoimmune disease prevalent across all ages, particularly in ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...